Available online www.jocpr.com

Journal of Chemical and Pharmaceutical Research, 2013, 5(1):254-260

Research Article

ISSN : 0975-7384
CODEN(USA) : JCPRC5

Synthesis, spectral analysis and *in vitro* biological evaluation of thiazolidinone derivatives of 5-nitroindazole

Neeta Rajput*[a], A. K. Sikarwar [a] and Adesh Dubey[b]

[a]Department of Chemistry, Govt. Girls Home Science P.G. College, Hoshangabad (M.P.) India
[b]Synthetic Organic Chemistry Laboratory, Department of Chemistry, Dr. Hari Singh Gour Central University, Sagar (M.P.) 470 003 India

---

ABSTRACT

A simple and efficient method has been developed for the synthesis of various 4-oxo-2-substituted phenyl-1,3-thiazolidine derivatives of 5-nitroindazole using conventional method. The series of 4-oxo-2-substituted phenyl-1,3-thiazolidine derivatives synthesized were structurally confirmed by analytical and spectral data and evaluated for their antimicrobial activities. Some compounds show that promising antibacterial and antifungal activities.

Keywords: Antibacterial, antifungal, 5-nitroindazole, thiazolidinone.

INTRODUCTION

The 5-nitroindazole ring system is probably the most important heyerocycle in nature. Owing to the great structural diversity of biologically active 5-nitroindazole, it is not surprising that the 5-nitroindazole ring system has become an important structural component in many pharmaceutical agents. Indazole ring possessing wide spectrum of pharmaceutical activities which include anti-inflammatory, antitumor, antiprotozoal, antimalarial, antiproliferative, analgesic, anticonvulsant, antimicrobial, antibacterial, antioxidant activity, etc [1-6]. The 4-oxo-thiazolidine and its derivatives have also taken a considerable pharmacological importance. The thiazolidine nucleus is a pharmacophoric scaffold and represents a class of heterocycles with a broad range of biological applications, such as anti-inflammatory, antitubercular, antiproliferative, DNA cleavage, cholesterol absorption inhibitors, Antiplasmodial, antidepressant, antimicrobial, etc. [7-14]. The biological and pharmaceutical significance of this class of compounds impelled us to synthesyze new types of 5-nitro indazole derivatives. In view of these facts, we report here in the synthesis some new N-{[(4-oxo-2-substituted phenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole as antimicrobial agents.

EXPERIMENTAL SECTION

All the melting points were determined by open capillary method. All reagents were obtained from Sigma-Aldrich chemicals Pvt. Ltd. Solvents were commercially obtained as laboratory grade. All chemicals were used after further purification (recrystalization or distillation). TLC was carried out on silica gel G coated glass plates. The purification of the compounds was crried out by column chromatography using 100-200 mesh Silica gel. ^{1}H-NMR spectra were recorded on a Bruker DRX 300 instrument at 300 MHz in $CDCl_3$ on δ scale in ppm using TMS as a reference. ^{13}C-NMR spectra were recorded on a Varian AMX 400 spectrophotometer at 50 MHz using $CDCl_3$. The FTIR spectra were recorded on a Perkin-elmer IR spectrophotometer using KBr disc of the sample in cm^{-1}. Mass spectra of the synthesized compounds have been recorded on a JEOL SX 102/DA-6000 spectrometer.

Evaluation of antimicrobial screening

All the synthesized compounds of series **5(a-m)** were tested for their antimicrobial activity. For antibacterial screening a gram-positive bacterium *S. aureus* and two gram-negative becteria, *E.Coli* and *S.pneumoniae* were used. For antifungal activity *C.albicans*, *A. pumigatus* and *A.niger* was taken. Antibacterial and antifungal screenings were performed by dilution method using nutrient agar media. MIC was determined at seven concentrations (in µg/ml) ranging from 1.0 µg, 2.5 µg, 5.0 µg, 10.0 µg, 20.0 µg, 25.0 µg and 50.0 µg of each compounds. The tubes were incubated at 37ºC for 48 hrs. DMSO was used as solvent. The lowest concentration, which showed no visible growth, was taken as an end point for minimum inhibitory concentration (MIC). Norflaxacin was used as standard drug for antibacterial screening in a concentration 1.0 µg/ml/disc and grysofulvin was used as standard drug for antifungal screening in a concentration 1.0 µg/ml/disc. The MIC levels of some active compounds **5(a-m)** against these organisms are given in table I.

General Procedure of the synthesis

Synthetic Protocol for the synthesis of N-(chloro butyl)-5-nitroindazole (2)

5-nitroindazole **(1)** (0.30 mol) was dissolved in methanol (100 ml) and 1-bromo-4-chlorobutane (0.30 mol) was added. The mixture was refluxed for about 5 hrs, filtered and the solvent was evaporated to dryness in vacuo. The crude product was readily purified by passing it through a chromatographic column packed with silica gel using chloroform: methanol (9:1 v/v) as eluant to obtain pure derivative. The resulting purified product was recrystalized by ethanol to give compounds **2**. M.P. 192-193ºC; IR: 3048 (C-H in Ar.), 2872, 2891 (C-H in CH_2), 1569 (C=N), 1464 (C=C), 1365 (Ar-NO_2), 1325 (N-CH_2), 738 (C-Cl). ^{1}H-NMR: 6.85-7.66 (m, 3H, Ar.), 3.64 (t, 2H, J=7.00, $CH_2CH_2CH_2CH_2$), 2.84 (t, 2H, J=7.00, $CH_2CH_2CH_2CH_2$), 1.90 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 110.61-144.15 (Ar.), 48.44, 43.28, 32.13, 29.68. MS, m/z: 254 $(M)^+$. Anal. calcd. for $C_{11}H_{12}N_3O_2Cl$: C, 52.07; H, 4.73; N, 16.56. Found: C, 52.03; H, 4.69; N, 16.53.

Synthesis of N-(hydrazino butyl)-5-nitroindazole (3)

Compound **2** (0.149 mol) was dissolved in acetone (50 ml) and hydrazine hydrate (0.149 mol) was added. The well stirred (1 hr) mixture was refluxed for 6 hrs. After cooling and filtration the solvent was evaporated under in vacuo to obtain a solid crude product. This resulting crude product was purified by passing it through a chromatographic column packed with silica gel using acetone: methanol (9:1 v/v) as eluant to obtain pure derivative. The resulting purified product was recrystalized by ethanol to give compounds **3**. M.P. 205-206ºC; IR: 3378 (-NH_2), 3345 (NH), 3045 (C-H in Ar.), 2874, 2892 (C-H in CH_2), 1564 (C=N), 1467 (C=C), 1361 (Ar-NO_2), 1327 (N-CH_2). ^{1}H-NMR: 7.85 (s, 1H, NH), 6.78-7.62 (m, 3H, Ar.), 3.72 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 2.88 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 1.76 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: (50 MHz, $CDCl_3$) δ: 113.63-146.21 (Ar.), 51.24, 42.49, 32.16, 30.58. MS, m/z: 249$(M)^+$. Anal. Calcd. for $C_{11}H_{15}N_5O_2$:C, 53.01; H, 6.02; N, 12.85. Found: C, 52.94; H, 5.98; N, 12.82.

Synthesis of N-[(benzylidene hydrazino)-butyl]-5-nitroindazole (4a-m)

A mixture of compound **3** (0.008 mol) and benzaldehyde (0.008 mol) in methanol (25 ml) in the presence of a catalytic amount of glacial acetic acid was refluxed for 5 hrs. The solvent was removed under reduced pressure to and the resulting crude product was purified by passing it through a chromatographic column packed with silica gel using chloroform : methanol (8:2 v/v) as eluant. Resulting purified product was recrystalized by chloroform to give compounds, **4a**.

N-[(benzylidene hydrazino)-butyl]-5-nitroindazole (4a). M.P. 220-221ºC: IR: 3351 (NH), 3043 (C-H in Ar.), 2872, 2888 (C-H in CH_2), 1586 (N=CH, azomethine), 1568 (C=N), 1461 (C=C), 1365 (Ar-NO_2), 1333 (N-CH_2). ^{1}H-NMR: 8.20 (s, 1H, N=CH, azomethine), 7.85 (s, 1H, NH), 6.74-7.78 (m, 9H, Ar.), 3.75 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 2.85 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 1.71 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 111.24-148.21 (Ar.), 138.84 (N=CH, azomethine), 48.56, 44.27, 31.48, 29.52. MS, m/z: 337$(M)^+$. Anal. Calcd. for $C_{18}H_{19}N_5O_2$: C, 64.09; H, 5.63; N, 20.77. Found : C, 64.04; H, 5.60; N, 20.74.

Other compounds **4b-m** was synthesized in the similar manner by treating compound **3** with selected aromatic aldehydes (**Scheme 1**).

N-[(2-chlorobenzylidene hydrazino)-butyl]-5-nitroindazole (4b).). M.P. 226-227ºC: IR: 3356 (NH), 3049 (C-H in Ar.), 2868, 2891(C-H in CH_2), 1591 (N=CH, azomethine), 1572 (C=N), 1464 (C=C), 1362 (Ar-NO_2), 1335 (N-CH_2). ^{1}H-NMR: 8.28 (s, 1H, N=CH, azomethine), 7.88 (s, 1H, NH), 6.72-7.76 (m, 8H, Ar.), 3.72 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 2.78 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 1.73 (m, 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 109.32-149.45 (Ar.), 140.42 (N=CH, azomethine), 48.74, 44.93, 32.41, 29.45. MS, m/z: 372 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_5O_2Cl$: C, 58.14; H, 4.84; N, 18.84. Found : C, 58.11; H, 4.80; N, 18.79.

N-[(3-chlorobenzylidene hydrazino)-butyl]-5-nitroindazole (4c). M.P. 229-230ºC: IR: 3358 (NH), 3054 (C-H in Ar.), 2866, 2892 (C-H in CH_2), 1594 (N=CH, azomethine), 1563 (C=N), 1467 (C=C), 1368 (Ar-NO_2), 1331 (N-CH_2). ^{1}H-NMR: 8.25 (s, 1H, N=CH, azomethine), 7.89 (s, 1H, NH), 6.75-7.72 (m, 8H, Ar.), 3.78 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 2.76 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 1.68 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 112.46-148.74 (Ar.), 140.52 (N=CH, azomethine), 48.98, 45.64, 32.46, 28.23. MS, m/z: 372 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_5O_2Cl$: C, 58.14; H, 4.84; N, 18.84. Found : C, 58.09; H, 4.81; N, 18.80.

N-[(4-chlorobenzylidene hydrazino)-butyl]-5-nitroindazole (4d). M.P. 222-223ºC: IR: 3355 (NH), 3051 (C-H in Ar.), 2868, 2889 (C-H in CH_2), 1588 (N=CH, azomethine), 1566 (C=N), 1462 (C=C), 1369 (Ar-NO_2), 1338 (N-CH_2). ^{1}H-NMR: 8.26 (s, 1H, N=CH, azomethine), 7.86 (s, 1H, NH), 6.68-7.75 (m, 8H, Ar.), 3.79 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 2.81 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 1.65 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 111.78-147.24 (Ar.), 139.76 (N=CH, azomethine), 49.16, 45.34, 31.94, 28.42. MS, m/z: 372 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_5O_2Cl$: C, 58.14; H, 4.84; N, 18.84. Found : C, 58.10; H, 4.81; N, 18.82.

N-[(2-bromobenzylidene hydrazino)-butyl]-5-nitroindazole (4e). M.P.215-216ºC: IR: 3352 (NH), 3059 (C-H in Ar.), 2863, 2886 (C-H in CH_2), 1585 (N=CH, azomethine), 1568 (C=N), 1463 (C=C), 1364 (Ar-NO_2), 1333 (N-CH_2). ^{1}H-NMR: 8.22 (s, 1H, N=CH, azomethine), 7.82 (s, 1H, NH), 6.75-7.71 (m, 8H, Ar.), 3.73 (t, 2H, J=7.10, $CH_2CH_2CH_2CH_2$), 2.77 (t, 2H, J=7.10, $CH_2CH_2CH_2CH_2$), 1.69 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 110.54-150.42 (Ar.), 138.54 (N=CH, azomethine), 48.24, 44.78, 31.74, 28.76. MS, m/z: 416 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_5O_2Br$: C, 51.92; H, 4.32; N, 16.82. Found : C, 51.89; H, 4.28; N, 16.77.

N-[(3-bromobenzylidene hydrazino)-butyl]-5-nitroindazole (4f). M.P. 212-213ºC: IR: 3358 (NH), 3055 (C-H in Ar.), 2865, 2890 (C-H in CH_2), 1589 (N=CH, azomethine), 1563 (C=N), 1465 (C=C), 1366 (Ar-NO_2), 1338 (N-CH_2). ^{1}H-NMR: 8.19 (s, 1H, N=CH, azomethine), 7.85 (s, 1H, NH), 6.66-7.76 (m, 8H, Ar.), 3.81 (t, 2H, J=7.50, $CH_2CH_2CH_2CH_2$), 2.84 (t, 2H, J=7.50, $CH_2CH_2CH_2CH_2$), 1.71 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 114.36-149.18 (Ar.), 139.82 (N=CH, azomethine), 47.63, 44.87, 32.62, 29.54. MS, m/z: 416 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_5O_2Br$: C, 51.92; H, 4.32; N, 16.82. Found : C, 51.88; H, 4.26; N, 16.79.

N-[(4-bromobenzylidene hydrazino)-butyl]-5-nitroindazole (4g). M.P. 216-217ºC: IR: 3353 (NH), 3058 (C-H in Ar.), 2867, 2884 (C-H in CH_2), 1583 (N=CH, azomethine), 1562 (C=N), 1469 (C=C), 1362 (Ar-NO_2), 1331 (N-CH_2). ^{1}H-NMR: 8.25 (s, 1H, N=CH, azomethine), 7.84 (s, 1H, NH), 6.78-7.74 (m, 8H, Ar.), 3.79 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 2.72 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 1.68 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 112.18-146.64 (Ar.), 138.12 (N=CH, azomethine), 48.82, 45.48, 31.53, 28.49. MS, m/z: 416 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_5O_2Br$: C, 51.92; H, 4.32; N, 16.82. Found : C, 51.90; H, 4.29; N, 16.78.

N-[(2-nitrobenzylidene hydrazino)-butyl]-5-nitroindazole (4h). M.P. 234-235ºC: IR: 3362 (NH), 3054 (C-H in Ar.), 2866, 2893 (C-H in CH_2), 1591 (N=CH, azomethine), 1575 (C=N), 1467 (C=C), 1367 (Ar-NO_2), 1339 (N-CH_2). ^{1}H-NMR: 8.30 (s, 1H, N=CH, azomethine), 7.92 (s, 1H, NH), 6.81-7.81 (m, 8H, Ar.), 3.85 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 2.88 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 1.75 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 110.55-151.58 (Ar.), 141.78 (N=CH, azomethine), 49.74, 45.92, 33.78, 30.34. MS, m/z: 382 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_6O_2$: C, 56.54; H, 4.71; N, 21.98. Found : C, 56.50; H, 4.66; N, 21.93.

N-[(3-nitrobenzylidene hydrazino)-butyl]-5-nitroindazole (4i). M.P. 229-230ºC: IR: 3361 (NH), 3056 (C-H in Ar.), 2863, 2898 (C-H in CH_2), 1588 (N=CH, azomethine), 1570 (C=N), 1461 (C=C), 1364 (Ar-NO_2), 1336 (N-CH_2). ^{1}H-NMR: 8.24 (s, 1H, N=CH, azomethine), 7.89 (s, 1H, NH), 6.79-7.78 (m, 8H, Ar.), 3.82 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 2.83 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 1.70 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 111.74-151.76 (Ar.), 142.64 (N=CH, azomethine), 50.52, 46.84, 33.16, 30.72. MS, m/z: 382 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_6O_2$: C, 56.54; H, 4.71; N, 21.98. Found : C, 56.49; H, 4.68; N, 21.96.

N-[(4-nitrobenzylidene hydrazino)-butyl]-5-nitroindazole (4j). M.P. 236-237ºC: IR: 3364 (NH), 3053 (C-H in Ar.), 2868, 2895 (C-H in CH_2), 1590 (N=CH, azomethine), 1572 (C=N), 1464 (C=C), 1368 (Ar-NO_2), 1332 (N-CH_2). ^{1}H-NMR: 8.26 (s, 1H, N=CH, azomethine), 7.87 (s, 1H, NH), 6.75-7.77 (m, 8H, Ar.), 3.84 (t, 2H, J=7.10, $CH_2CH_2CH_2CH_2$), 2.85 (t, 2H, J=7.10, $CH_2CH_2CH_2CH_2$), 1.73 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 109.34-150.28 (Ar.), 141.84 (N=CH, azomethine), 49.88, 46.66, 32.94, 30.16. MS, m/z: 382 $(M)^+$. Anal. Calcd. for $C_{18}H_{18}N_6O_2$: C, 56.54; H, 4.71; N, 21.98. Found : C, 56.51; H, 4.67; N, 21.95.

N-[(2-methoxybenzylidene hydrazino)-butyl]-5-nitroindazole (4k). M.P. 216-217ºC: IR: 3353 (NH), 3056 (C-H in Ar.), 2861, 2885 (C-H in CH_2), 1588 (N=CH, azomethine), 1564 (C=N), 1468 (C=C), 1365 (Ar-NO_2), 1331 (N-CH_2). ^{1}H-NMR: 8.28 (s, 1H, N=CH, azomethine), 7.79 (s, 1H, NH), 6.71-7.68 (m, 8H, Ar.), 3.78 (t, 2H, J=7.08, $CH_2CH_2CH_2CH_2$), 2.78 (t, 2H, J=7.08, $CH_2CH_2CH_2CH_2$), 1.66 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 113.86-148.36

(Ar.), 139.65 (N=CH, azomethine), 49.43, 44.28, 31.05, 29.14. MS, m/z: 367 $(M)^+$. Anal. Calcd. for $C_{19}H_{21}N_5O_3$: C, 62.12; H, 5.72; N, 19.07. Found : C, 62.08; H, 5.68; N, 19.04.

N-[(3-methoxybenzylidene hydrazino)-butyl]-5-nitroindazole (4l). M.P. 222-223ºC: IR: 3358 (NH), 3058 (C-H in Ar.), 2864, 2888 (C-H in CH_2), 1584 (N=CH, azomethine), 1569 (C=N), 1465, (C=C), 1362 (Ar-NO_2), 1337 (N-CH_2). ^{1}H-NMR: 8.23 (s, 1H, N=CH, azomethine), 7.81 (s, 1H, NH), 6.80-7.66 (m, 8H, Ar.), 3.75 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 2.79 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 1.63 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 108.22-148.58 (Ar.), 139.81 (N=CH, azomethine), 48.57, 43.52, 31.36, 28.92. MS, m/z: 367 $(M)^+$. Anal. Calcd. for $C_{19}H_{21}N_5O_3$: C, 62.12; H, 5.72; N, 19.07. Found : C, 62.07; H, 5.69; N, 19.03.

N-[(4-methoxybenzylidene hydrazino)-butyl]-5-nitroindazole (4m). M.P. 220-221ºC: IR: 3357 (NH), 3055 (C-H in Ar.), 2865, 2890 (C-H in CH_2), 1587 (N=CH, azomethine), 1568 (C=N), 1469, (C=C), 1367 (Ar-NO_2), 1336 (N-CH_2). ^{1}H-NMR: 8.27 (s, 1H, N=CH, azomethine), 7.85 (s, 1H, NH), 6.82-7.72 (m, 8H, Ar.), 3.76 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 2.75 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 1.68 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 112.42-147.25 (Ar.), 138.96 (N=CH, azomethine), 48.64, 44.22, 30.86, 29.24. MS, m/z: 367 $(M)^+$. Anal. Calcd. for $C_{19}H_{21}N_5O_3$: C, 62.12; H, 5.72; N, 19.07. Found : C, 62.09; H, 5.68; N, 19.05.

Synthesis of N-{[(4-oxo-2-substituted phenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5a).
A mixture of compound **4a** (0.003 mol) and $SHCH_2COOH$ (0.01 mol) in methanol, containing a pinch of anhy. $ZnCl_2$ was first stirred (2 hrs) followed by refluxed on a steam bath for about 7 hours. The reaction mixture was cooled and excess of solvent was evaporated under reduced pressure. The solid obtained was purified by passing it through a chromatographic column packed with Silica gel using chloroform: methanol (9:1 v/v) as eluant and recrystallised from ethanol to give compounds **5a**. M.P. 239-240 ºC: IR: 3352 (N-H), 3046 (C-H in Ar.), 2931 (C-H in S-CH_2), 2858, 2878 (C-H in CH_2), 1738 (C=O), 1562 (C=N), 1445 (C=C), 1363 (Ar-NO_2), 1335 (N-CH_2), 734 (C-S-C). ^{1}H-NMR: 8.14 (s, 1H, NH), 6.84-7.79 (m, 9H, Ar.), 5.48 (s, 1H, N-CH-S), 3.35 (s, 2H, $COCH_2S$), 3.75 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 2.58 (t, 2H, J=7.20,$CH_2CH_2CH_2CH_2$), 1.59 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 168 (C=O), 111.12-154.56 (Ar.), 64.32 (N-CH), 34.88 ($COCH_2S$), 48.33, 42.28, 33.22, 29.44. MS, m/z: 411 $(M)^+$. Anal. Calcd. for $C_{20}H_{21}N_5O_3S_1$: C, 58.39; H, 5.10; N, 17.03. Found : C, 58.34; H, 5.06; N, 17.00.

Other compounds **5b-m** was synthesized in the similar manner by treating compound **4b-m** (Scheme 1).

N-[{4-oxo-2-(2-chlorophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5b).
M.P.245-246 ºC: IR: 3356 (N-H), 3048 (C-H in Ar.), 2935 (C-H in S-CH_2), 2856, 2880 (C-H in CH_2), 1745 (C=O), 1564 (C=N), 1436 (C=C), 1364 (Ar-NO_2), 1334 (N-CH_2), 745 (Ar-Cl), 735 (C-S-C). ^{1}H-NMR: 8.11 (s, 1H, NH), 6.78-7.73 (m, 9H, Ar.), 5.52 (s, 1H, N-CH-S), 3.36 (s, 2H, $COCH_2S$), 3.78 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 2.55 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 1.58 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 170.36 (C=O), 113.66-153.28 (Ar.), 64.48 (N-CH), 35.16 ($COCH_2S$), 49.14, 42.68, 33.84, 29.92. MS, m/z: 446 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_5O_3S_1Cl_1$: C, 53.87; H, 4.48; N, 15.71. Found : C, 53.85; H, 4.43; N, 15.66.

N-[{4-oxo-2-(3-chlorophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5c).
M.P.242-243 ºC: IR: 3355 (N-H), 3051 (C-H in Ar.), 2933 (C-H in S-CH_2), 2858, 2881 (C-H in CH_2), 1742 (C=O), 1568 (C=N), 1434 (C=C), 1366 (Ar-NO_2), 1342 (N-CH_2), 746 (Ar-Cl), 736 (C-S-C). ^{1}H-NMR: 8.16 (s, 1H, NH), 6.76-7.80 (m, 9H, Ar.), 5.51 (s, 1H, N-CH-S), 3.32 (s, 2H, $COCH_2S$), 3.74 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 2.56 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 1.56 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 170.74 (C=O), 114.25-155.22 (Ar.), 65.84 (N-CH), 35.24 ($COCH_2S$), 49.54, 43.16, 33.78, 30.52. MS, m/z: 446 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_5O_3S_1Cl_1$: C, 53.87; H, 4.48; N, 15.71. Found : C, 53.84; H, 4.45; N, 15.65.

N-[{4-oxo-2-(4-chlorophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5d).
M.P. 246-247ºC: IR: 3358 (N-H), 3049 (C-H in Ar.), 2936 (C-H in S-CH_2), 2860, 2883 (C-H in CH_2), 1744 (C=O), 1563 (C=N), 1438 (C=C), 1364 (Ar-NO_2), 1338 (N-CH_2), 748 (Ar-Cl), 733 (C-S-C). ^{1}H-NMR: 8.15 (s, 1H, NH), 6.80-7.82 (m, 9H, Ar.), 5.54 (s, 1H, N-CH-S), 3.29 (s, 2H, $COCH_2S$), 3.76 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 2.59 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 1.61 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 169.86 (C=O), 110.34-149.86 (Ar.), 65.18 (N-CH), 36.52 ($COCH_2S$), 49.74, 43.48, 32.98, 30.18. MS, 446 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_5O_3S_1Cl_1$: C, 53.87; H, 4.48; N, 15.71. Found : C, 53.85; H, 4.46; N, 15.67.

N-[{4-oxo-2-(2-bromophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5e).
M.P.236-237: IR: 3354 (N-H), 3051 (C-H in Ar.), 2932 (C-H in S-CH_2), 2862, 2884 (C-H in CH_2), 1738 (C=O), 1567 (C=N), 1437 (C=C), 1369 (Ar-NO_2), 1346 (N-CH_2), 730 (C-S-C), 655 (Ar-Br). ^{1}H-NMR: 8.12 (s, 1H, NH), 6.81-7.76 (m, 9H, Ar.), 5.46 (s, 1H, N-CH-S), 3.35 (s, 2H, $COCH_2S$), 3.77 (t, 2H, J=7.10, $CH_2CH_2CH_2CH_2$), 2.54 (t, 2H, J=7.10, $CH_2CH_2CH_2CH_2$), 1.63 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 166.42 (C=O), 112.38-150.62 (Ar.), 64.62

(N-CH), 34.84 ($COCH_2S$), 47.64, 43.28, 31.82, 29.88. MS, m/z: 490 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_5O_3S_1Br_1$: C, 48.97; H, 4.08; N, 14.28. Found : C, 48.94; H, 4.03; N, 14.23.

SCHEME1



S. No.	R	S. No.	R
a	H	g	4-Br
b	2-Cl	H	2-NO_2
c	3-Cl	i	3-NO_2
d	4-Cl	j	4-NO_2
e	2-Br	k	2-OCH_3
f	3-Br	l	3-OCH_3
		m	4-OCH_3

N-[{4-oxo-2-(3-bromophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5f).
M.P.219-220: IR: 3352 (N-H), 3053 (C-H in Ar.), 2934 (C-H in S-CH_2), 2856, 2881 (C-H in CH_2), 1739 (C=O), 1566 (C=N), 1435 (C=C), 1362 (Ar-NO_2), 1347 (N-CH_2), 729 (C-S-C), 656 (Ar-Br). ^{1}H-NMR: 8.14 (s, 1H, NH), 6.72-7.77 (m, 9H, Ar.), 5.49 (s, 1H, N-CH-S), 3.33 (s, 2H, $COCH_2S$), 3.72 (t, 2H, J=7.50, $CH_2CH_2CH_2CH_2$), 2.58 (t, 2H, J=7.50, $CH_2CH_2CH_2CH_2$), 1.57 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 167.38 (C=O), 109.98-148.58 (Ar.), 64.74 (N-CH), 34.72 ($COCH_2S$), 48.68, 43.76, 33.12, 29.74. MS, m/z: 490 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_5O_3S_1Br_1$: C, 48.97; H, 4.08; N, 14.28. Found : C, 48.93; H, 4.05; N, 14.26.

N-[{4-oxo-2-(4-bromophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5g).
M.P.229-230 ºC: IR: 3355 (N-H), 3057 (C-H in Ar.), 2931 (C-H in S-CH_2), 2859, 2883 (C-H in CH_2), 1737 (C=O), 1565 (C=N), 1438 (C=C), 1366 (Ar-NO_2), 1348 (N-CH_2), 731 (C-S-C), 653 (Ar-Br). ^{1}H-NMR: 8.13 (s, 1H, NH), 6.83-7.81 (m, 9H, Ar.), 5.48 (s, 1H, N-CH-S), 3.36 (s, 2H, $COCH_2S$), 3.79 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 2.57 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 1.60 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 165.98 (C=O), 113.72-150.42 (Ar.), 65.54 (N-CH), 35.46 ($COCH_2S$), 48.24, 43.52, 33.42, 29.68. MS, m/z: 490 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_5O_3S_1Br_1$: C, 48.97; H, 4.08; N, 14.28. Found : C, 48.95; H, 4.04; N, 14.25.

N-[{4-oxo-2-(2-nitrophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5h).
M.P. 246-247ºC: IR: 3361 (N-H), 3058 (C-H in Ar.), 2939 (C-H in S-CH_2), 2862, 2886 (C-H in CH_2), 1745 (C=O), 1573 (C=N), 1443 (C=C), 1368 (Ar-NO_2), 1345 (N-CH_2), 737 (C-S-C). ^{1}H-NMR: 8.19 (s, 1H, NH), 6.87-7.85 (m, 9H, Ar.), 5.51 (s, 1H, N-CH-S), 3.38 (s, 2H, $COCH_2S$), 3.81 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 2.59 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 1.65 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 171.12 (C=O), 114.26-154.63 (Ar.), 66.62 (N-CH),

37.18 ($COCH_2S$), 49.76, 44.12, 34.56, 30.68. MS, m/z: 456 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_6O_5S_1$: C, 52.63; H, 4.38; N, 18.42. Found : C, 52.58; H, 4.35; N, 18.37.

N-[{4-oxo-2-(3-nitrophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5i).
Yield- M.P. 239-240ºC: IR: 3362 (N-H), 3056 (C-H in Ar.), 2936 (C-H in S-CH_2), 2863, 2889 (C-H in CH_2), 1746 (C=O), 1572 (C=N), 1441 (C=C), 1364 (Ar-NO_2), 1349 (N-CH_2), 735 (C-S-C). ^{1}H-NMR: 8.22 (s, 1H, NH), 6.79-7.88 (m, 9H, Ar.), 5.55 (s, 1H, N-CH-S), 3.35 (s, 2H, $COCH_2S$), 3.83 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 2.62 (t, 2H, J=7.15, $CH_2CH_2CH_2CH_2$), 1.66 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 170.48 (C=O), 111.82-153.92 (Ar.), 67.28 (N-CH), 36.48 ($COCH_2S$), 49.94, 44.02, 34.18, 30.46. MS, 456 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_6O_5S_1$: C, 52.63; H, 4.38; N, 18.42. Found : C, 52.57; H, 4.34; N, 18.38.

N-[{4-oxo-2-(4-nitrophenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5j).
M.P. 241-242 ºC: IR: 3360 (N-H), 3059 (C-H in Ar.), 2938 (C-H in S-CH_2), 2865, 2888 (C-H in CH_2), 1748 (C=O), 1574 (C=N), 1444 (C=C), 1366 (Ar-NO_2), 1346 (N-CH_2), 738 (C-S-C). ^{1}H-NMR: 8.20 (s, 1H, NH), 6.85-7.86 (m, 9H, Ar.), 5.52 (s, 1H, N-CH-S), 3.38 (s, 2H, $COCH_2S$), 3.78 (t, 2H, J=7.08, $CH_2CH_2CH_2CH_2$), 2.64 (t, 2H, J=7.08, $CH_2CH_2CH_2CH_2$), 1.63 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 169.44 (C=O), 112.16-152.76 (Ar.), 66.94 (N-CH), 36.94 ($COCH_2S$), 50.12, 43.84, 33.98, 30.16. MS, 456 $(M)^+$. Anal. Calcd. for $C_{20}H_{20}N_6O_5S_1$: C, 52.63; H, 4.38; N, 18.42. Found : C, 52.59; H, 4.35; N, 18.37.

N-[{4-oxo-2-(2-methoxyphenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5k).
M.P. 233-234ºC: IR: 3353 (N-H), 3055 (C-H in Ar.), 2935 (C-H in S-CH_2), 2857, 2886 (C-H in CH_2), 1741 (C=O), 1568 (C=N), 1437 (C=C), 1367 (Ar-NO_2), 1341 (N-CH_2), 1255 (Ar-OCH_3), 733 (C-S-C). ^{1}H-NMR: 8.17 (s, 1H, NH), 6.74-7.80 (m, 9H, Ar.), 5.53 (s, 1H, N-CH-S), 3.31 (s, 2H, $COCH_2S$), 3.76 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 2.60 (t, 2H, J=7.25, $CH_2CH_2CH_2CH_2$), 1.58 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 166.74 (C=O), 110.68-150.64 (Ar.), 64.22 (N-CH), 33.54 ($COCH_2S$), 48.62, 43.68, 32.98, 29.54. MS, m/z: 441 $(M)^+$. Anal. Calcd. for $C_{21}H_{23}N_5O_4S_1$: C, 57.14; H, 5.21; N, 15.87. Found : C, 57.09; H, 5.18; N, 15.82.

N-[{4-oxo-2-(3-methoxyphenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5l).
M.P.238-239ºC: IR: 3356 (N-H), 3050 (C-H in Ar.), 2937 (C-H in S-CH_2), 2853, 2885 (C-H in CH_2), 1739 (C=O), 1566 (C=N), 1436 (C=C), 1365 (Ar-NO_2), 1339 (N-CH_2), 1255 (Ar-OCH_3), 732 (C-S-C). ^{1}H-NMR: 8.14 (s, 1H, NH), 6.76-7.83 (m, 9H, Ar.), 5.50 (s, 1H, N-CH-S), 3.30 (s, 2H, $COCH_2S$), 3.75 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 2.61 (t, 2H, J=7.30, $CH_2CH_2CH_2CH_2$), 1.57 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 168.72 (C=O), 111.72-148.94 (Ar.), 63.98 (N-CH), 34.84 ($COCH_2S$), 49.62, 43.78, 33.34, 29.84. MS, 441 $(M)^+$. Anal. Calcd. for $C_{21}H_{23}N_5O_4S_1$: C, 57.14; H, 5.21; N, 15.87. Found : C, 57.11; H, 5.15; N, 15.84.

N-[{4-oxo-2-(4-methoxyphenyl)-1,3-thiazolidineimino]-butyl}-5-nitroindazole (5m).
M.P. 235-236 ºC: IR: 3354 (N-H), 3047 (C-H in Ar.), 2934 (C-H in S-CH_2), 2857, 2882 (C-H in CH_2), 1743 (C=O), 1565 (C=N), 1434 (C=C), 1362 (Ar-NO_2), 1344 (N-CH_2), 1253 (Ar-OCH_3), 731 (C-S-C). ^{1}H-NMR: 8.15 (s, 1H, NH), 6.80-7.81 (m, 9H, Ar.), 5.51 (s, 1H, N-CH-S), 3.29 (s, 2H, $COCH_2S$), 3.79 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 2.58 (t, 2H, J=7.20, $CH_2CH_2CH_2CH_2$), 1.56 (m 4H, $CH_2CH_2CH_2CH_2$). ^{13}C-NMR: 165.82 (C=O), 111.78-151.54 (Ar.), 64.16 (N-CH), 34.12 ($COCH_2S$), 48.84, 43.48, 32.34, 29.44. MS, m/z: 441 $(M)^+$. Anal. Calcd. for $C_{21}H_{23}N_5O_4S_1$: C, 57.14; H, 5.21; N, 15.87. Found : C, 57.10; H, 5.16; N, 15.83.

RESULTS AND DISCUSSION

Our synthesis strategy was based on to synthesize a highly biologically active heterocyclic compound containing 5-nitroindazole and thiazolidinone moieties. As the results, we synthesized a series of thiazolidinone derivatives of 5-nitroindazole by scheme **1**.

5-nitroindazole **(1)** on reaction with 1-bromo-4-chloro butane got converted into their chlorobutyl derivative (**2**), which on hydrazinolysis of with hydrazine hydrate afforded hydrazide derivative (**3**). A new series of compounds **4(a-m)** was synthesised by treating of different aromatic aldehydes with compound (**3)** in the presence of a catalytic amount of glacial acetic acid. The target compounds **5(a-m)** furnished by treatment of thioglycolic acid in the presence of anhydrous $ZnCl_2$ with compounds **4(a-m)**.

All the synthesized compounds of series **(5a-m)** were tested for their antimicrobial activity, against some selected bacteria and fungi. Generally compounds possessing electronegative groups showed good antibacterial activity. Compounds possessing electron donating groups have shown good antifungal activity. Activity data are given in the

table **I**. It is thus concluded that new synthesized azetidinones are good antimicrobial compounds for therapeutic uses.

Table-I: Antibacterial and Antifungal activity of Compounds 4a-m (MIC μg/ml)

No.	*S.aures*	*E.coli*	*S.pneumoe*	*C.albicas*	*A.fumigats*	*A.niger*
4a	25.0	10.0	50.0	20.0	10.0	20.0
4b	1.0	2.5	5.0	1.0	5.0	5.0
4c	2.5	5.0	2.5	5.0	10.0	5.0
4d	5.0	5.0	10.0	1.0	2.5	2.5
4e	2.5	5.0	5.0	2.5	1.0	5.0
4f	2.5	1.0	2.5	2.5	2.5	1.0
4g	5.0	5.0	10.0	2.5	5.0	5.0
4h	1.0	1.0	2.5	10.0	5.0	10.0
4i	5.0	2.5	2.5	5.0	10.0	5.0
4j	2.5	2.5	5.0	10.0	5.0	2.5
4k	10.0	5.0	5.0	10.0	10.0	5.0
4l	10.0	2.5	2.5	5.0	2.5	5.0
4m	5.0	2.5	5.0	5.0	10.0	10.0
Norflaxacin	1.0	1.0	1.0			
Grysofulvin				1.0	1.0	1.0

Acknowledgement
The authors thanks to SAIF, CDRI Lucknow for providing FTIR, ^{1}H-NMR, ^{13}C-NMR and mass spectral analysis data of the compound. We are also grateful microcare laboratory and tuberculosis research center for antimicrobial activity. Thanks are also due to the Head, Department of Chemistry, Dr. H. S. Gour University, Sagar (M.P.) and Govt. Girls Home Science P.G. College, Hoshangabad (M.P.) India for laboratories facilities to carry out the work.

REFERENCES

[1] EB Gabriel; NS Iryna; H Michaela; AJ Michael; KK Bernhard; H Petra B Walter; BA Vladimir. *J Inorg Biochem* **2012**, 113, 47-54.
[2] AS Said; EA Abd El-Galil; MS Nermien; MA Mohamed. *Eur J Med Chem*, **2009**, 44, 4787–4792.
[3] A Upadhyay; SK Srivastava; SD Srivastava. *Eur J Med Chem*, **2010**, 45, 3541-3548.
[4] ASA Nasir; Z Shaikh; P Muqtadir; F Mazahar. *Eur J Med Chem*, **2012**, 50, 39-43.
[5] G Laurent; S Emmanuelle; A Georges; D Eric; A Fabrice; M Pascale. *Eur J Med Chem*, **2010**, 45, 5520-5526.
[6] S Jaroslaw; H Alan; S Mika; R Apolonia; M Daqing; S Franciszek; L Shayna; ML Jonne; B Konrad; L Artur; G Jianteng; W Helena. *Bioorg & Medi Chem*, **2012**, 20, 108–116.
[7] SAE Mohamed; AMEA Gameel; AE-M Ahmed; TAEl-R Mohamed; HMH Mohamed. *Eur J Med Chem*, **2009,** 44, 4148–4152.
[8] ARR Fernando; NGS Rory; VE Santiago; G-B Alicia; F Diego; A Torres; M-S Berta; JN-R Juan; RM-F Antonio; VK Vladimir. *Bioorg & Medi Chem*, **2011**, 19, 4562–4573.
[9] L Yan; W Zhao; C-M Li; C Jianjun; TD James; L Wei; DM Duane. *Bioorg & Med Chem*, **2010**, 18, 477–495.
[10] C Hua; B Jie; J Lingling; G Zaihong; Y Qingmei; L Xiaoliu. *Bioorg & Med Chem*, **2009**, 17, 3980–3986.
[11] P Divyesh; K Premlata; P Navin. *Eur J Med Chem*, **2012**, 48, 354-362.
[12] S Avula; N Adki; SR Cherkupally. *Eur J Med Chem*, **2010**, 45, 2353-2358.
[13] AK Salman; Y Mohammed. *Eur J Med Chem*, **2009**, 44, 2597–2600.
[14] MF Hassan; AK Khalid; MA Abdullah. *J Fluorine Chem*, **2011**, 132, 870–877.